- Report
- April 2024
- 181 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- February 2024
- 115 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- February 2024
- 120 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- February 2024
- 125 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- February 2024
- 110 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- February 2024
- 120 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- April 2024
- 65 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- January 2024
- 90 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- April 2024
- 185 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 182 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 180 Pages
Global
From €4729EUR$4,900USD£4,057GBP
Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more